

Molecular Docking Study of *Nigella sativa* Bioactive Compound as E6 Inhibitor Against Human Papillomavirus (HPV) Infection

Received 14 Desember 2022,
Accepted 21 Desember 2022,

DOI: 10.24036/sainstek/vol1-
iss02/7

Ahmad Affan Ali Murtadlo¹, Priscilla Listiyani¹, Santika Lusia Utami², Sri Wahyuningsih², Dora Dayu Rahma Turista³, Arbi Wiguna⁴, Arini Wijayanti⁵, Yuanita Rachmawati⁶, Alyaa Farrah Dibha⁷, Thobib Hasan⁸, Muhammad Aldino Hafidzhah⁹, Renadya Maulani Wijaya⁹, Agus Mohammad Hikam¹⁰, Muhammad Badrut Tamam^{11*}, Nelson Chandra⁹, Md. Emdad Ullah¹²

¹Computational Virology Research Unit, Molecular Biology and Genetics Division, Generasi Biologi Indonesia Foundation, Gresik Indonesia.

²Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, Indonesia.

³Educational Biology Department, Faculty of Teacher Training and Education, Mulawarman University, Samarinda, Indonesia.

⁴Zoology Division, Generasi Biologi Indonesia Foundation, Gresik, Indonesia.

⁵Department of Ecology and Evolutionary Biology, University of California Santa Cruz, Santa Cruz, United States.

⁶Department of Biology, Faculty of Science and Technology, UIN Sunan Ampel Surabaya, Surabaya, Indonesia.

⁷Chemistry Department, Faculty of Mathematics and Natural Sciences, Brawijaya University, Malang, Indonesia.

⁸Department of Biology, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia.

⁹Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life-Sciences, East Jakarta, Indonesia.

¹⁰Faculty of Mathematics and Natural Sciences, Universitas Islam Malang, Malang, Indonesia.

¹¹Department of Biology, Faculty of Sciences and Technology, Universitas Muhammadiyah Lamongan, Lamongan, Indonesia.

¹²Department of Chemistry, Mississippi State University, Mississippi State, United States.

*Corresponding Author: mh.badruttamam@gmail.com

ABSTRACT

HPV can trigger cancer cases in the laryngeal, lung, oral, and anogenital. Classification of HPV based on the ability to trigger cancer, HPV is divided into two types consisting of high risk (HR) and low risk (LR). HPV-6 and HPV-11 are low-risk types or only cause precancerous lesions or warts. In the case of lesion progression to intraepithelial malignancies triggered by infection with HPV-16 and HPV-18 types. Previous studies used E6 to target antiviral drug design, the drug works by inhibiting E6 activity and preventing p53 degradation. *Nigella sativa* is widely used as traditional medicine by

† Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/sainstek/vol1-iss02/7

people around the world for generations. This research is important because it is to identify the molecular mechanism of chemical compounds from *Nigella sativa* as a candidate agent for high-risk HPV type of antiviral through inhibition of E6 activity. The inhibition of the E6-p53 complex by the Longifolene compound from *Nigella sativa* causes a decrease in E6 activity and an increase in p53 protein activity, then normal cells will not develop into cancer. Inhibition of the E6-p53 complex will also trigger apoptosis in cells that have been infected with HPV.

Keywords: Bioactive, HPV, Inhibitor, Molecular Docking, *Nigella sativa*

INTRODUCTION

Human Papillomavirus is the causative agent of multiple epithelial lesions and cancer. There are currently about 100 subtypes worldwide¹. HPV can trigger pathogenesis in humans through the initiation of increased proliferation and immortalization of host cells through the activation of specific oncoproteins. HPV tropism is epithelial cells and basal stem cells^{2,3}. HPV is composed of dsDNA and is non-enveloped, the virion has a capsid that is encoded by the L1 & L2 genes, the gene is expressed late⁴. Infectious protein from HPV is activated through early protein (E) consisting of E2, E5, E6, & E7. HPV early protein plays a role in triggering viral replication, protein synthesis, assembly, and increased host cell proliferation^{5,6}. Classification of HPV based on the ability to trigger cancer, HPV is divided into two types consisting of high risk (HR) and low risk (LR)^{7,8}.

HPV can trigger cancer cases in the laryngeal, lung, oral, and anogenital. HPV-6 and HPV-11 are low-risk types or only cause precancerous lesions or warts^{9,10}. In the case of lesion progression to intraepithelial malignancies triggered by infection with HPV-16 and HPV-18 types. HPV has specific oncoproteins consisting of E6 & E7, which act to inhibit tumor suppressors such as p53 & pRb, it affects the cell cycle, then triggers cellular transformation into cancer cells^{11,12}. E6 plays a crucial role in triggering the inhibitory activity and degradation of p53. E6 will recruit ubiquitin at the E6-p53 complex, it can trigger degradation via the ubiquitin proteasome^{13,14}. Previous studies used E6 to target antiviral drug design, the drug works by inhibiting E6 activity and preventing p53 degradation.

Nigella sativa is widely used as traditional medicine by people around the world for generations^{15,16}. These medicinal plants also play a therapeutic role in cases of diseases such as diabetes, cancer, and others^{17,18}. Other potentials such as antibacterial and antiprotozoa. *Nigella sativa* has activity as an antioxidant, immunomodulator, and a few are used for antiviral^{19,20}.

This research is important because it is to identify the molecular mechanism of chemical compounds from *Nigella sativa* as a candidate agent for high-risk HPV type of antiviral through inhibition of E6 activity.

METHODS

Ligand-protein retrieval

The chemical compounds of *Nigella sativa* are Thymol (CID 6989), Phenol, 3-(1,1-dimethylethyl)-4-methoxy- (CID 6932), Eicosanoic acid (CID 10467), p-tert-Butyl catechol (CID 7381), & Longifolene (CID 289151), Canonical SMILE, molecular weight, and 3D structures in sdf files were obtained from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>). The target in this study was E6 HPV-16 (PDB ID: 4XR8) obtained from the RCSB PDB database (<https://www.rcsb.org/>) with pdb files^{21,22}.

Energy minimization and 3D structure sterilization

The sdf file must be converted to pdb via OpenBabel v2.4.1 software. to obtain a pdb file, the process of changing the format to increase ligand flexibility through energy minimization method, then water molecules and contaminant ligands on the target protein are removed through PyMol v2.5 software to obtain maximum binding energy during docking simulations^{23,24,25}.

Molecular docking simulation

Molecular docking simulation in this study aims to identify compounds from *Nigella sativa* as inhibitors of HPV-16 E6 protein activity. The simulation was carried out using PyRx v0.9.9 software with an autogrid covering the entire surface of target. The activity level of the query compound refers to the binding affinity score formed, the more negative it is, the stronger the possibility of ligand binding to the specific domain of the target protein. The docked molecular complexes are displayed on sticks, cartoons, and transparent surfaces through PyMol v2.5 software through the structural selection method^{26,27,28}.

Ligand-protein Interaction

Weak bonds play a role in ligands to produce an activity response to proteins. The ligand-protein interactions formed are weak bonds, weak bonds such as hydrogen, electrostatic, alkyl, van der Waals, and hydrophobic. The Discovery Studio 2016 software version was used in this study to identify the weak bonds formed in molecular complexes²⁹.

Structural Visualization

Molecular visualization of the ligand-protein complex was carried out using PyMol v2.5 software through staining and structural selection methods. The 3D structure shown consists of cartoons, surfaces, and sticks, staining is done on the protein constituent chains³⁰.

RESULT AND DISCUSSION

Revealing of inhibitor molecular mechanism from *Nigella sativa* compound

Nigella sativa in people's lives around the world is used for traditional medicine such as anti-inflammatory, antiviral, preventing free radicals, and others³¹. *Nigella sativa* was identified to have chemical compounds consisting of Thymol, Phenol, 3-(1,1-dimethylethyl)-4-methoxy-, Eicosanoic acid, p-tert-Butyl catechol, & Longifolene (Table 1). This study used a chemical compound from *Nigella sativa* to identify candidate antiviral drugs against HPV by inhibiting the activity of oncoprotein E6 by molecular docking simulation with autogrid positions are center (Å) X: -54.007 Y: -3.836 Z: -14.773 dimensions (Å) X: 66.209 Y: 50.535 Z: 54.869.

Table 1. *Nigella sativa* chemical compound from PubChem

Compound	CID	Formula	SMILE Canonical
Thymol	6989	C ₁₀ H ₁₄ O	CC1=CC(=C(C=C1)C(C)C)O
Phenol, 3-(1,1-dimethylethyl)-4-methoxy-	6932	C ₁₁ H ₁₆ O ₂	C11H16O2 CC(C)(C)C1=C(C=CC(=C1)O)OC
Eicosanoic acid	10467	C ₂₀ H ₄₀ O ₂	CCCCCCCCCCCCCCCCCCCC(=O)O
p-tert-Butyl catechol	7381	C ₁₀ H ₁₄ O ₂	CC(C)(C)C1=CC(=C(C=C1)O)O
Longifolene	289151	C ₁₅ H ₂₄	CC1(CCCC2(C3C1C(C2=C)CC3)C)C

Longifolene has a binding affinity of -6.4 kcal/mol more negative than other compounds when it binds to E6 protein (Table 2), Longifolene is predicted to inhibit the activity of E6 protein in HPV because it has more negative binding than other compounds. The molecular docking simulation aims to determine the activity of the ligand binding on the protein domain by referring to the

binding affinity value. The binding affinity value indicates the inhibitory ability of a ligand on the activity of the target protein³². Visualization of docking results is displayed through cartoons structure and sticks with selected coloring (Figure 1).

Table 2. The comparison of compound binding affinity

Compound	Molecular Weight (g/mol)	Minimize Energy (kcal/mol)	Binding Affinity (kcal/mol)
Thymol	150.22	+120.83	-5.4
Phenol, 3-(1,1-dimethylethyl)-4-methoxy-	180.24	+247.37	-5.1
Eicosanoic acid	312.5	+3394.99	-4.7
p-tert-Butyl catechol	166.22	+106.31	-5.6
Longifolene	204.35	+534.45	-6.4




Figure 1. 3D Visualization from the docking results. (A) E6_Thymol (B) E6_Phenol, 3-(1,1-dimethylethyl)-4-methoxy- (C) E6_Eicosanoic acid (D) E6_p-tert-Butyl catechol (E) E6_Longifolene.

Molecular interaction at E6 protein

Chemical bond interactions in molecular complexes are identified to determine the type of bond and position^{33,35}. All ligands have the same interaction position at Leu74, Tyr39, Val60, Val38, Phe52, Gln114, Val69, and Leu57, this position allows them to act as potential domains to lead inhibitory activity at E6 (Table 2). Weak bond interactions such as van der Waals, hydrogen, and alkyl are also formed in all ligands, Longifolene has more hydrogen bond interactions than other compounds and this can strengthen the prediction

that Longifolene can act as a good drug candidate. Weak bond interactions consisting of hydrogen, hydrophobic, and alkyl can play a role in triggering the response of biological activity on the target protein^{36,37}. The number of hydrogen bonds can be used as an indicator of the stability of a drug candidate molecule^{38,39}. Thus, Longifolene is predicted to become a drug molecule because it can affect the activity of E6 protein through weak bonds and has the highest number of hydrogen bonds.

Table 2. Chemical interaction on E6 pocket binding domain

Compounds	Molecular Interaction
Longifolene	van der Waals: <u>Val38</u> , <u>Val60</u> , <u>Ala68</u> , <u>Leu74</u> , <u>Tyr39</u> , <u>Gln114</u> , <u>Leu107</u> , <u>Phe52</u> Hydrogen: Tyr77, Cys58 Alkyl: <u>Val69</u> , <u>Leu57</u>
Phenol, 3-(1,1-dimethylethyl)-4-methoxy-	van der Waals: <u>Phe52</u> , Ser81, Tyr77, <u>Gln114</u> , <u>Val60</u> Alkyl: <u>Leu57</u> , <u>Val38</u> , <u>Leu74</u> , <u>Tyr39</u> , <u>Val69</u> ,
Eicosanoic acid	van der Waals: <u>Tyr39</u> , <u>Ala68</u> , <u>Gln114</u> , Alkyl: <u>Val69</u> , <u>Val60</u> , <u>Val38</u> , <u>Phe52</u> , <u>Leu74</u> , <u>Leu57</u>
p-tert-Butyl catechol	van der Waals: <u>Ala68</u> , <u>Gln114</u> , Arg109, <u>Tyr39</u> Alkyl: <u>Leu57</u> , <u>Val69</u> , <u>Val38</u> , <u>Val60</u> , <u>Phe52</u> , <u>Leu74</u> , Cys58
Thymol	van der Waals: <u>Phe52</u> , <u>Ala68</u> , <u>Tyr39</u> , <u>Gln114</u> Alkyl: <u>Val60</u> , <u>Val69</u> , <u>Val38</u> , <u>Leu74</u> , <u>Leu57</u> , Cys58,

Nigella sativa is an HPV antiviral candidate to prevent the development of cervical cancer through the binding of Longifolene to the E6 domain. Longifolene compounds can produce a more negative binding affinity than others and produce weak binding interactions to trigger an E6 inhibitor response through the Leu74, Tyr39, Val60, Val38, Phe52, Gln114, Val69,

and Leu57 domains. The inhibition of the E6-p53 complex by the Longifolene compound causes a decrease in E6 activity and an increase in p53 protein activity, then normal cells will not develop into cancer⁴⁰. Inhibition of the E6-p53 complex will also trigger apoptosis in cells that have been infected with HPV.

CONCLUSION

Nigella sativa can act as an antiviral through the binding activity of Longifolene compounds in preventing the E6-p53 complex through the specific domains the Leu74, Tyr39, Val60, Val38, Phe52, Gln114, Val69, and Leu57 through weak bond interactions and are stable because Longifolene have a large number of hydrogen bonds. We recommend the E6-binding domain for further research as a target for HPV drug design and the results of this study are yet to be verified through wet lab testing.

REFERENCES

- Baig A, Srinivasan H. SARS-CoV-2 Inhibitors from *Nigella Sativa*. *Appl Biochem Biotechnol*. 2022; 194(3): 1051-1090. DOI: 10.1007/s12010-021-03790-8.
- Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the Rule of 5 and drugability. *Adv Drug Deliv Rev*. 2016;101:89-98. DOI: 10.1016/j.addr.2016.05.007.
- Ansori ANM, Fadholly A, Proboningrat A, Antonius Y, Hayaza S, Susilo RJ, Inayatillah B, Sibero MT, Naw SW, Posa GAV, Sucipto TH, Soegijanto S. Novel Antiviral Investigation of *Annona squamosa* Leaf Extract against the Dengue Virus Type-2: In vitro Study. *Phcog J*. 2021; 13(2): 456-462. DOI: 10.5530/pj.2021.13.58
- Ansori AN, Kharisma VD, Parikesit AA, Dian FA, Probojati RT, Rebezov M, Scherbakov P, Burkov P, Zhdanova G, Mikhalev A, Antonius Y, Pratama MRF, Sumantri NI, Sucipto TH, Zainul R. Bioactive Compounds from Mangosteen (*Garcinia mangostana* L.) as an Antiviral Agent via Dual Inhibitor Mechanism against SARS-CoV-2: An In Silico Approach. *Phcog J*. 2022; 14(1): 85-90. DOI: 10.5530/pj.2022.14.12
- Wijaya RM, Hafidzhah MA, Kharisma VD, Ansori ANM, Parikesit AP. COVID-19 In Silico Drug with *Zingiber officinale* Natural Product Compound Library Targeting the Mpro Protein. *Makara J Sci*. 2021; 25(3): 5. DOI: 10.7454/mss.v25i3.1244
- Fahmi M, Kharisma VD, Ansori ANM, Ito M. Retrieval and Investigation of Data on SARS-CoV-2 and COVID-19 Using Bioinformatics Approach. *Adv Exp Med Biol*. 2021; 1318: 839-857. DOI: 10.1007/978-3-030-63761-3_47.
- Winarni D, Husna FN, Syadzha MF, Susilo RJK, Hayaza S, Ansori ANM, Alamsjah MA, Amin MNG, Wulandari PAC, Pudjiastuti P, Awang K. Topical Administration Effect of *Sargassum duplicatum* and *Garcinia mangostana* Extracts Combination on Open Wound Healing Process in Diabetic Mice. *Scientifica*. 2022; 2022: 9700794. DOI: 10.1155/2022/9700794.
- Khairullah AR, Solikhah TI, Ansori ANM, Hanisia RH, Puspitarani GA, Fadholly A, Ramandinianto SC. Medicinal importance of *Kaempferia galanga* L. (Zingiberaceae): A comprehensive review. *J Herbmed Pharmacol*. 2021; 10: 281-288. DOI: 10.34172/jhp.2021.32
- Kharisma VD, Probojati RT, Murtadlo AAA, Ansori ANM, Antonius Y, Tamam MB. Revealing Potency of Bioactive Compounds as Inhibitor of Dengue Virus (DENV) NS2B/NS3 Protease from Sweet Potato (*Ipomoea batatas* L.) Leaves. *Indian J Forensic Med Toxicol*. 2020; 15(1): 1627–1632. DOI: 10.37506/ijfmt.v15i1.13644
- Kharisma VD, Agatha A, Ansori ANM, Widyananda MH, Rizky WC, Dings TGA, Derkho M, Lykasova I, Antonius Y, Rosadi I, Zainul R. Herbal combination from *Moringa oleifera* Lam. and *Curcuma longa* L. as SARS-CoV-2 antiviral via dual inhibitor pathway: A viroinformatics approach. *J Pharm Pharmacogn Res*. 2022; 10(1): 138-146.
- Ansori ANM, Susilo RJK, Fadholly A, Hayaza S, Nugraha AP, Husen SA. Antidiabetes type 2 phytomedicine: Mangosteen (*Garcinia Mangostana* L.)-A review. *Biochem Cell Arch*. 2020; 20: 3173-3177. DOI: 10.35124/bca.2020.20.S1.3173
- Khairullah AR, Solikhah TI, Ansori ANM, Fadholly A, Ramandinianto SC, Ansharieta R, Widodo A, Riwu KHP, Putri N, Proboningrat A, Kusala MKJ, Rendragraha BW, Putra ARS, Anshori A. A Review of an Important Medicinal Plant: *Alpinia galanga* (L.) Willd. *Sys Rev Pharm*. 2020; 11(10): 387-395. DOI: 10.31838/srp.2020.10.62
- Kharisma VD, Widyananda MH, Ansori ANM, Nege AS, Naw SW, Nugraha AP. Tea catechin as antiviral agent via apoptosis agonist and triple inhibitor mechanism against HIV-1 infection: A bioinformatics approach. *J Pharm Pharmacogn Res*. 9(4): 435-445.
- Kharisma VD, Ansori ANM, Widyananda MH, Utami SL, Nugraha AP. Molecular simulation: The potency of conserved region on E6 HPV-16

- as a binding target of black tea compounds against cervical cancer. *Biochem Cell Arch.* 2020; 20: 2795-2802. DOI: 10.35124/bca.2020.20.S1.2795
15. Widyananda MH, Pratama SK, Samoedra RS, Sari FN, Kharisma VD, Ansori ANM, Antonius Y (2021) Molecular docking study of sea urchin (*Arbacia lixula*) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. *J Pharm Pharmacogn Res* 9(4): 484–496.
 16. Tacharina MR, Ansori ANM, Plumeriastuti H, Kusnoto , Kurnijasanti R, Hestianah EP. Beneficial effect of grinting grass (*Cynodon dactylon*) on the streptozotocin induced diabetes mellitus in the mice. *Indian Vet J.* 2020; 97(4): 35-38.
 17. Wahyuni DK, Ansori ANM, Vidiyanti F. GC-MS analysis of phytochemicals in methanolic extracts of leaf-derived callus of *Justicia gendarussa* Burm.f. *Biosci Res.* 2017;14(3):668-677.
 18. Husen SA, Winarni D, Salamun, Ansori ANM, Susilo RJK, Hayaza S. Hepatoprotective Effect of Gamma-mangostin for Amelioration of Impaired Liver Structure and Function in Streptozotocin-induced Diabetic Mice. *IOP Conf Ser: Earth Env Sci.* 2019; 217(1): 012031. DOI: 10.1088/1755-1315/217/1/012031
 19. Ansori ANM, Kusala MKJ, Irawan H, Putri N, Fadholly A, Proboningrat A, Rukmana Siti, Karni I, Anisa AK, Adrianto H. Citrus *reticulata* extract as biocides to control *Aedes aegypti*, the vector of dengue. *Biosci Res.* 2018; 15(3): 1661-1665.
 20. Ansori ANM, Sucipto TH, Chylichcova S, Padi H, Kharisma VD, Widyananda MH, Ullah E, Gumenyuk O, Prasedya ES, Sibero MT, Bratishko N, Zainul R. Macroalgae Bioactive Compounds for the Potential Antiviral of SARS-CoV-2: An In Silico Study. *Journal of Pure and Applied Microbiology.* 2022; 16(2): 1018-1027. DOI: 10.22207/JPAM.16.2.26
 21. Fadholly A, Ansori ANM, Utomo B. Anticancer Effect of Naringin on Human Colon Cancer (WiDr Cells): In Vitro Study. *Research Journal of Pharmacy and Technology.* 2022; 15(2): 885-888. DOI: 10.52711/0974-360X.2022.00148
 22. Dibha AF, Wahyuningsih S, Ansori ANM, Kharisma VD, Widyananda MH, Parikesit AA, Sibero MT, Probojati RT, Murtadlo AAA, Trinugroho JP, Sucipto TH, Turista DDR, Rosadi I, Ullah ME, Jakhmola V, Zainul R. Utilization of Secondary Metabolites in Algae *Kappaphycus alvarezii* as a Breast Cancer Drug with a Computational Method. *Pharmacognosy Journal.* 2022; 14(3): 536-543. DOI: 10.5530/pj.2022.14.68
 23. Aini NS, Ansori ANM, Kharisma VD, Syadzha MF, Widyananda MH, Murtadlo AA, et al. Potential Roles of Purslane (*Portulaca oleracea* L.) as Antimetabolic Syndrome: A Review. *Pharmacognosy Journal.* 2022; 14(3): 710-714. DOI: 10.5530/pj.2022.14.90
 24. Listiyani P, Kharisma VD, Ansori AN, Widyananda MH, Probojati RT, Murtadlo AA, et al. In Silico Phytochemical Compounds Screening of *Allium sativum* Targeting the Mpro of SARS-CoV-2. *Pharmacognosy Journal.* 2022; 14(3): 604-609. DOI: 10.5530/pj.2022.14.78
 25. Naw SW, Probojati RT, Murtadlo, AAA, Ullah, ME. (2022). Computational Drug Design Study of *Curcuma longa* L. Compound as HPV-16 Antiviral Candidate Against Cervical Cancer. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics,* 1(01), 1–6.
 26. Ullah ME, Probojati RT, Murtadlo AAA, Tamam MB, Naw WR. Revealing of Antiinflammatory Agent from *Zingiber officinale* var. *Roscoe* via IKK-B Inhibitor Mechanism through In Silico Simulation. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics.* 2022; 1(01): 14–19.
 27. Ullah ME, Naw WR, Murtadlo AAA, Tamam MB, Probojati RT. Molecular Mechanism of Black Tea (*Camellia sinensis*) as SARS-CoV-2 Spike Glycoprotein Inhibitor through Computational Approach. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics.* 2022; 1(01): 20–25.
 28. Probojati RT, Murtadlo AAA, Ullah ME, Naw WR, Turista DDR. Molecular Docking Study of HIV-1 Antiretroviral Candidate via Reverse Transcriptase Inhibitor from *Zingiber officinale* var. *Roscoe*. *SAINSTEK International Journal on Applied Science, Advanced Technology and Informatics.* 2022; 1(01): 26–31.
 29. Tamam MB, Naw WR, Ullah ME, Probojati RT, Murtadlo AAA, Turista DDR. Virtual Screening of *Kaempferia galanga* L. Bioactive Compounds as HPV-16 Antiviral Mechanism Through E6 Inhibitor Activity. *SAINSTEK International*

- Journal on Applied Science, Advanced Technology and Informatics. 2022; 1(01): 7–13.
30. Ansori ANM, Fadholly A, Hayaza S, Susilo RJK, Inayatillah B, Winarni D, Husen SA. A Review on Medicinal Properties of Mangosteen (*Garcinia mangostana* L.). *Res J Pharm Technol.* 2020; 13(2):974-982. doi: 10.5958/0974-360X.2020.00182.1
 31. Husen SA, Wahyuningsih SPA, Ansori ANM, Hayaza S, Susilo RJK, Winarni D, Punnapayak H, Darmanto W. Antioxidant Potency of Okra (*Abelmoschus esculentus* Moench) Pods Extract on SOD Level and Tissue Glucose Tolerance in Diabetic Mice. *Res J Pharm Technol.* 12(12): 5683. doi: 10.5958/0974-360X.2019.00983.1
 32. Husen SA, Setyawan MF, Syadzha MF, Susilo RJK, Hayaza S, Ansori ANM, Alamsjah MA, Ilmi ZN, Wulandari PAC, Pudjiastuti P, Awang P, Winarni D. A Novel Therapeutic effects of *Sargassum ilicifolium* Alginate and Okra (*Abelmoschus esculentus*) Pods extracts on Open wound healing process in Diabetic Mice. *Research J. Pharm. and Tech* 2020; 13(6): 2764-2770. doi: 10.5958/0974-360X.2020.00491.6
 33. Kharisma VD, Kharisma SD, Ansori ANM, Kurniawan HP, Witaningrum AM, Fadholly A, Tacharina MR. Antiretroviral Effect Simulation from Black Tea (*Camellia sinensis*) via Dual Inhibitors Mechanism in HIV-1 and its Social Perspective in Indonesia. *Res J Pharm Technol.* 2021; 14(1): 455-460. doi: 10.5958/0974-360X.2021.00083.4
 34. Fadholly A, Ansori ANM, Kharisma VD, Rahmahani J, Tacharina MR. Immunobioinformatics of Rabies Virus in Various Countries of Asia: Glycoprotein Gene. *Res J Pharm Technol.* 2021; 14(2): 883-886. doi: 10.5958/0974-360X.2021.00157.8
 35. Ansori ANM, Fadholly A, Proboningrat A, Hayaza S, Susilo RJK, Naw SW, Posa GAV, Yusrizal YF, Sibero MT, Sucipto TH, Soegijanto S. In vitro antiviral activity of *Pinus merkusii* (Pinaceae) stem bark and cone against dengue virus type-2 (DENV-2). *Res J Pharm Technol.* 2021; 14(7):3705-8. doi: 10.52711/0974-360X.2021.00641
 36. Ansori ANM, Kharisma VD, Fadholly A, Tacharina MR, Antonius Y, Parikesit AA. Severe Acute Respiratory Syndrome Coronavirus-2 Emergence and Its Treatment with Alternative Medicines: A Review. *Research Journal of Pharmacy and Technology* 2021; 14(10):5551-7. doi: 10.52711/0974-360X.2021.00967
 37. Husen SA, Ansori ANM, Hayaza S, Susilo RJK, Zuraidah AA, Winarni D, Punnapayak H, Darmanto W. Therapeutic Effect of Okra (*Abelmoschus esculentus* Moench) Pods Extract on Streptozotocin-Induced Type-2 Diabetic Mice. *Res J Pharm Technol.* 2019; 12(8):3703-3708. doi: 10.5958/0974-360X.2019.00633.4
 38. Ansori ANM, Kharisma VD, Solikhah TI. Medicinal properties of *Muntingia calabura* L.: A Review. *Res J Pharm Technol.* 2021; 14(8):4509-2. doi: 10.52711/0974-360X.2021.00784
 39. Proboningrat A, Kharisma VD, Ansori ANM, Rahmawati R, Fadholly A, Posa GAV, Sudjarwo SA, Rantam FA, Achmad AB. In silico Study of Natural inhibitors for Human papillomavirus-18 E6 protein. *Res J Pharm Technol.* 2022; 15(3):1251-6. doi: 10.52711/0974-360X.2022.00209
 40. Kharisma VD, Ansori ANM, Jakhmola V, Rizky WC, Widyananda MH, Probojati RT, Murtadlo AAA, Rebezov M, Scherbakov P, Burkov P, Matrosova Y, Romanov A, Sihombing MAEM, Antonius Y, Zainul R. Multi-strain human papillomavirus (HPV) vaccine innovation via computational study: A mini review. *Res J Pharm Technol.* 2022; 15(8).